# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad downgrades Revance Therapeutics (NASDAQ:RVNC) from Overweight to Equal-Weight and lowers the ...
Needham analyst Serge Belanger downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Hold.
Guggenheim analyst Seamus Fernandez downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral.
William Blair analyst Tim Lugo downgrades Revance Therapeutics (NASDAQ:RVNC) from Outperform to Market Perform.
Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.